Press Releases

Investor and Media Contacts

Investors

DeDe Sheel
650-376-6492
dsheel@aimmune.com

Media

Julie Normart
559-974-3245
jnormart@w2ogroup.com

Lauren Barbiero
646-564-2156
lbarbiero@w2ogroup.com

ShareThis Copy and Paste

Aimmune Therapeuticsat the Bank of America Merrill Lynch Healthcare Conference
Tuesday, May 16, 2017 1:00 p.m. PT

Webcast Presentation

Help

Click here for webcast

— "Real-World" Trial Will Augment Ongoing Phase 3 PALISADE Trial to Support Regulatory Filings and Market Understanding — BRISBANE, Calif.--(BUSINESS WIRE)--May 11, 2017-- Aimmune Therapeutics, Inc. (Nasdaq:AIMT), today announced the enrollment of its first patient in the Phase 3 RAMSES (ARC007) clinical trial of AR101 for treatment of peanut allergy. AR101 is Aimmune's investigational biologic oral immunotherapy for desensitization of patient...

Press Releases

Keyword Search

Recent News

Investor and Media Contacts

Investors

Media